D-Pharm considers plugging gap with Thrombotech buy

D-Pharm has confirmed that it is in talks to acquire fellow Israeli firm Thrombotech. D-Pharm is keen to fill quickly the gap left by the failure of its lead product candidate DP-b99, which was in pivotal Phase III trials as a treatment for acute ischaemic stroke until January this year when an advisory committee concluded that it had little chance of success.

"We are at the beginning of due diligence and negotiations," it told Scrip. "The potential acquisition is likely to be...